TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

Tibotec Pharmaceuticals, Ireland330 enrolled

Overview

The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.

A phase II randomized, controlled, partially blinded, trial to investigate dose response of TMC114/RTV in HIV-1 infected patients who have previously received all three licensed classes of HIV antiviral drugs (known as nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI)), and who are on a stable PI-containing regimen not including an NNRTI may be eligible to participate. Four doses of TMC-114/ritonavir will be studied. 300 patients in the United States and Puerto Rico will participate. The duration of the study is 96 weeks. Randomize to one of 4 treatment groups (TMC114/RTV: 400/100 mg qd; 800/100mg qd; 400/100mg bid; 600/100 bid) or control arm for 24 to 48 wks. Optimal dose (TMC114/RTV 600/100mg bid) open label portion of the study. The trial was extended to include 144Wks of treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

330

Conditions

HIV Infections

Interventions

TMC114/rtvDRUG

800mg TMC114/100mg rtv once daily

TMC114/rtvDRUG

400mg TMC114/100mg rtv both twice daily

TMC114/rtvDRUG

400mg TMC114/100mg rtv once daily

TMC114/rtv

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, age 18 years or older * Documented HIV-1 infection * Stable PI regimen for at least 8 weeks prior to screening * Plasma viral load at screening above 1000 HIV-1 RNA copies/ml * Prior use of more than 1 NRTI for at least 3 months * Prior use of one or more NNRTIs as part of a failing regimen * At least 1 primary PI mutation as defined by the IAS guidelines * Treatment with at least 1 PI for a total of at least 3 months * Patient has given informed consent Exclusion Criteria: * Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection * Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures * NNRTI as part of therapy at screening * Patients on a treatment interruption at screening * Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening * Hepatitis A, B, or C.

Locations (39)

Outcomes

Primary Outcomes

To evaluate the dose-response relationship of antiviral activity of the TMC114/RTV dose regimens at 24 Wks in order to determine the optimal dose.

Time frame: 24 weeks

Secondary Outcomes

To evaluate safety and tolerability over 24 to 144Wks; The durability of the antiviral activity; The effect of functional monotherapy with TMC114 over 2 weeks in different doses; and The dose-response by comparing the different TMC114/RTV dosages.

Time frame: 144 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Beverly Hills, California, United States

Unnamed facility

Long Beach, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Oakland, California, United States

Unnamed facility

San Diego, California, United States

Unnamed facility

San Francisco, California, United States

Unnamed facility

West Hollywood, California, United States

Unnamed facility

Denver, Colorado, United States

...and 29 more locations